Browsing: Longevity Risk
Longevity and Mortality Investor’s coverage of bulk purchase annuity transactions. We are a leading source globally for longevity risk analysis, commentary and insights.
Two pension schemes sponsored by CF Fertilisers UK Limited, the UK subsidiary of a global manufacturer of hydrogen and nitrogen products for clean energy, have completed bulk purchase annuity buy-in transactions with M&G.
New study finds that while the number of new policy settlements declined in 2024, long-term growth drivers remain strong.
The past four decades have brought revolutionary improvements in cancer care, transforming many forms of cancer from fatal diagnoses into chronic, manageable conditions.
For those in the longevity and mortality modelling game, 2025 has provided plenty of activity to keep the actuaries busy. Greg Winterton spoke to James Hadley, Senior Consultant at Barnett Waddingham, to learn more about what is front and centre of the conversation in his world as the year draws to a close.
Deal is the second step in the BBC Pension Scheme’s phased longevity hedging programme.
Finalised in September 2025, the transaction provides long-term security for the benefits of nearly 10,000 members and secures all remaining uninsured defined benefits in the plan.
The aggregate surplus of the 4,969 schemes in the Pension Protection Fund’s 7800 Index increased by £16.2bn through October 2025, rising to £271.3bn in surplus, and the funding ratio rose by 0.7 percentage points to 129.8% and the number of schemes in surplus rose to 3,844, representing more than three-quarters (77.4%) of all schemes in the universe.
Changes to the NCOIL life settlement model act in the past 25 years have been beneficial to the life settlement market but educating consumers, policyholders and investors remains the rising tide that will lift all boats.
A year after the UK Pensions Regulator’s code of practice on funding for defined benefit (DB) pension schemes was launched, the UK’s pension risk transfer market remains buoyant, suggesting the guidance has had little material effect on deals.
Within the life settlement industry, the medical record review has long remained one of the most resource-intensive and time-consuming stages of the process but recent advancements in automation and artificial intelligence, however, are beginning to change this dynamic.